The body uses them as a temporary brake on inflammation
In the ongoing effort to understand why COVID-19 strikes some people gently and others with devastating force, researchers at Emory University have found an unexpected clue hiding in the nose itself — the very place where the virus first takes hold. Their two-year study of 125 patients revealed that autoantibodies appearing in nasal passages early in infection appear to act as a protective brake on inflammation, while the same class of proteins found in the blood signal the opposite: serious illness. This inversion of conventional immunological wisdom, paired with a new diagnostic tool capable of reading the immune response from a single nasal swab in real time, opens a door toward faster, more personalized care for those most vulnerable to respiratory disease.
- COVID-19 has always been many diseases at once, and medicine has struggled to predict — in time to act — which version any given patient will face.
- The discovery that nasal autoantibodies correlate with milder outcomes while blood autoantibodies signal severe disease upends a foundational assumption: that autoantibodies are uniformly dangerous.
- Years of antibody research missed this distinction entirely because it focused on blood, the convenient sample, rather than the nose, the actual site of infection.
- A newly developed technology called FlowBEAT can now detect dozens of antibody types simultaneously from a standard nasal swab, transforming a routine test into a real-time map of immune activity.
- For high-risk patients, this could compress the window for life-saving antiviral treatment from uncertain waiting to informed, early intervention.
- Researchers are now asking whether this protective nasal mechanism extends to influenza and RSV — a question that, if answered yes, could reframe how science understands autoimmunity itself.
The coronavirus has never behaved as a single disease. Some people barely notice it; others end up hospitalized. Researchers at Emory University have now found something unexpected at the place where COVID-19 actually begins: the nose.
Over nearly two years, they followed 125 patients across the full range of infection severity, measuring antibodies in both blood and nasal passages. More than 70 percent of people with mild or moderate illness developed autoantibodies — proteins the body makes against its own tissues — in their nasal cavities. Normally, autoantibodies are a warning sign, evidence of an immune system attacking itself. But in the nose, they appeared to do the opposite: arriving early, targeting an inflammatory molecule, and dampening the immune fire rather than feeding it. As patients recovered, these nasal autoantibodies faded, as if the body had used them as a temporary brake and then released it.
The critical twist: autoantibodies found in the blood told an entirely different story, predicting worse outcomes. The same class of immune response, in two different locations, carried two opposite meanings. Senior researcher Eliver Ghosn noted that previous studies had missed this because they measured what was easy — blood — rather than what was relevant: the nasal passages where the virus first takes hold.
To make the finding clinically useful, Ghosn's lab developed FlowBEAT, a tool that measures dozens of antibody types simultaneously from a single nasal swab. Where traditional antibody testing is slow and narrow, FlowBEAT turns a routine diagnostic swab into a real-time window onto the immune response. For high-risk patients, this could mean receiving antivirals like Paxlovid within the critical first week rather than waiting to see how sick they become.
The team is now investigating whether this protective nasal autoantibody response appears in other respiratory infections such as flu and RSV. If it does, Ghosn believes it could constitute a paradigm shift in how immunologists understand protective immunity altogether. The lab is already working to develop a clinical diagnostic tool using material from standard nasal swabs already collected in clinics — a collaboration spanning Emory, UCSF, and the Gladstone Institutes.
The coronavirus has never been one disease. From the start, it has moved through the world in a thousand different ways—some people barely noticing it, others ending up in the hospital, still others not making it out. The current variants tend toward the gentler end of that spectrum, but anyone with an underlying condition knows the virus still carries weight. Now researchers at Emory University have found something unexpected in the place where COVID-19 actually begins: the nose.
For nearly two years, they followed 125 patients across the full range of infection severity, measuring antibodies in both blood and nasal passages. What they discovered upended conventional wisdom about how the immune system works. More than 70 percent of people with mild or moderate COVID-19 developed autoantibodies—proteins the body makes against itself—in their nasal cavities. Normally, autoantibodies are a red flag, a sign the immune system has gone haywire and is attacking its own tissues. But in the nose, after COVID-19 infection, they appeared to do the opposite. They showed up early, targeted an inflammatory molecule the body was producing, and seemed to dampen the fire rather than feed it. As people recovered, these nasal autoantibodies faded away, as if the body had used them as a temporary brake on inflammation and then let them go.
The twist that makes this finding matter: autoantibodies in the blood told a different story entirely. When researchers found them there, it predicted worse outcomes. The same type of immune response, in two different places, meant two entirely different things. "The key to this puzzle was to look directly at the site of infection, in the nose, instead of the blood," said Eliver Ghosn, the senior researcher on the study, published in Science Translational Medicine. "While autoantibodies in the blood were linked to bad prognosis, producing them only in the nose soon after infection is linked to efficient recovery." Previous studies had missed this distinction because they focused on what could be measured easily in blood samples, overlooking the actual battlefield where the virus first takes hold.
To make this discovery actionable, Ghosn's lab developed a new tool called FlowBEAT that can measure multiple types of antibodies simultaneously from a single nasal swab. Historically, antibody testing has been slow and limited, capable of measuring only one or a few at a time. FlowBEAT changes that. It can detect dozens of different viral and host antigens in a single tube, turning a routine diagnostic swab into a window onto the immune response happening in real time. For high-risk patients—those with chronic conditions or compromised immunity—this could mean the difference between getting early treatment with antivirals like Paxlovid within the critical first week and waiting to see how sick they get.
The researchers are now exploring whether this protective nasal autoantibody response exists in other respiratory infections. If it does, Ghosn suggests, it could reshape how immunologists think about autoimmunity itself. "If this nasal autoantibody response turns out to be a common mechanism to protect us against other viral infections, it can be a paradigm shift in how we study protective immunity," he said. The lab is working with Emory's patent office to develop a clinical diagnostic tool using leftover material from standard nasal swabs already being done in clinics. Ben Babcock, a PhD candidate who led the study, framed the possibility plainly: "Right now, we're either looking at infection risk before it happens or analyzing the infection course well after recovery. Imagine if we could capture the immune response in real-time, right in the clinic. A just-in-time test could give physicians and patients the real-time information they need to make faster, smarter treatment decisions." The research was a collaboration involving scientists from UCSF, Gladstone Institutes, and multiple Emory laboratories, suggesting the kind of distributed effort now required to understand how immunity actually works.
Notable Quotes
The key to this puzzle was to look directly at the site of infection, in the nose, instead of the blood.— Eliver Ghosn, senior researcher, Emory University
If this nasal autoantibody response turns out to be a common mechanism to protect us against other viral infections, it can be a paradigm shift in how we study protective immunity.— Eliver Ghosn
The Hearth Conversation Another angle on the story
So autoantibodies are usually bad news—they're the immune system attacking itself. How did you figure out they were actually helping here?
The breakthrough was looking at location. Everyone had been studying blood autoantibodies, which do predict severe disease. But COVID-19 starts in the nose. When we measured what was actually happening at the site of infection, the story flipped. The nasal autoantibodies appeared early, grabbed onto inflammatory molecules, and seemed to keep the immune response from spiraling out of control.
But they disappeared as people got better. So the body was using them temporarily?
Exactly. It's like the immune system deployed them as a specific tool for this moment, then withdrew them once the job was done. That's why they're protective rather than pathological.
And the blood autoantibodies—those still mean trouble?
Yes. They're associated with worse outcomes. Same type of protein, completely different meaning depending on where it shows up. That's why previous research missed it.
This FlowBEAT tool—it measures everything at once from a nasal swab?
Right. Instead of testing for one antibody at a time, it can detect dozens of different antigens simultaneously in a single sample. For a high-risk patient, you could know within hours whether they need immediate antiviral treatment.
What happens next?
They're testing whether this same protective mechanism exists in flu and RSV. If it does, it changes how we think about autoimmunity across all respiratory infections.